Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses future research directions with darolutamide (Nubeqa) for the treatment of patients with prostate cancer.
Currently, darolutamide has been approved to treat patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) throughout most of the world, Shore says. Darolutamide is a powerful androgen receptor pathway inhibitor (ARPI) and is similar to other ARPIs such as enzalutamide (Xtandi) and apalutamide (Erleada), Shore notes. Additional data that are expected to read out soon may lead to the expanded approval of the agent to extend its use to patients with metastatic CRPC, as well as metastatic castration-sensitive prostate cancer.
Obtaining real-world experience with available ARPIs is necessary, as these agents have demonstrated efficacy in delaying radiographic progression and providing an overall survival to patients with nmCRPC, according to Shore. Although enzalutamide and apalutamide currently have broader indications, it is beneficial to fully understand the safety and tolerability profile of darolutamide due to its potentially expanding indications, Shore concludes.